Based in Cleveland, Ohio, Neuronoff is developing injectable neuromodulation solutions designed to remove surgical barriers to treatment. The company's Injectrode platform has successfully completed first-in-human trials and is advancing toward FDA clearance in 2026, supported by comprehensive preclinical validation and positive regulatory interactions. The technology is intended to offer a minimally invasive alternative for chronic conditions ranging from pain to autonomic, bladder, cardiac, and inflammatory disorders.
